+ 1 888 391 5441

Steady Growth in China's Monoclonal Antibody Industry


A monoclonal antibody is a laboratory-produced molecule that mimics the antibodies produced naturally by the body. Presently, monoclonal antibodies have been used successfully for the treatment of various types of cancers, tumors and other serious diseases. Monoclonal antibody has also been used for treating autoimmune diseases including rheumatoid arthritis, ulcerative colitis, Chrohn’s disease, organ transplant rejection etc. In recent years, the monoclonal antibody market has grown rapidly mainly due to technological advancement, launch of new products, robust market demand and introduction of generic monoclonal antibody drugs. From 2009 to 2012, the global market for monoclonal antibody grew at a compound annual growth rate of 13%. This growth rate was higher than the growth rate of the biopharmaceuticals market during the same period. It is estimated that the growth of the monoclonal antibody market will be strong in the future. According to analysts, the market for monoclonal antibody is predicted to reach a value of 141 billion USD in 2017 with a compound annual growth rate of 12% between 2013 and 2017. In China, the monoclonal antibody industry is also showing steady growth which is expected to continue in the future.

Market Overview
In 2012, China accounted for 9.5% of the global monoclonal antibody market. It is estimated that China’s monoclonal antibody market will have a growth rate of around 35% from 2013 to 2017. By 2017, it is expected that the Chinese monoclonal market will account for 21.5% of the overall global market. There are more than 100 companies that are involved in the manufacture of monoclonal antibody agents in China. Out of these, 10 companies have conducted clinical trials. The Chinese monoclonal antibody market is dominated by imported products such as Rituximab, Infliximab, Trastuzumab and Bevacizumab, which occupied around 70-75% of the overall market share in 2012. Foreign pharmaceutical companies such as Novartis Pharmaceuticals and Roche are the market leaders in the China’s monoclonal antibody industry. China’s domestic monoclonal industry is still at its nascent stage and the growth has been slow due to constrain in research and development and technological barrier.

Globally, the monoclonal antibody market is dominated by companies from America and Europe. Major global companies include Roche, Johnson & Johnson, Amgen and AbbVie. Some of the key domestic players in China’s monoclonal antibody industry are Beijing Biotech Pharmaceutical Company, Shanghai Meien Biotechnology, Wuhan Institute of Biological Products, Shanghai CP Guojian Pharmaceutical and Chengdu Huasun Group. As China has the world’s largest population, there is a huge market for health care. Due to this, the monoclonal antibody market in China is expected to flourish in the future.

Explore the latest market research reports on China’s monoclonal antibody industry @ http://www.chinamarketresearchreports.com/114686.html

Why http://www.chinamarketresearchreports.com
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy